Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Herbert Gritsch

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
British Journal of Haematology|May 19, 2004
Mutation of the surface-exposed amino acid Trp to Ala in the FVIII C2 domain results in defective secretion of the otherwise functional proteinSimone M Schatz, Klaus Zimmermann, Meinhard Hasslacher, et al.
Seminars in Thrombosis and Hemostasis|May 7, 2002
Recombinant von Willebrand factor-insight into structure and function through infusion studies in animals with severe von Willebrand diseaseHans Peter Schwarz, Uwe Schlokat, Artur Mitterer, et al.
Hamostaseologie|March 28, 2018
The role of ultralarge multimers in recombinant human von Willebrand factor - a review of physico-and biochemical studies and findings in in vivo models and in humans with von Willebrand diseasePeter L Turecek, Michael Spannagl, Thorsten Kragh, et al.
Journal of Thrombosis and Haemostasis : JTH|January 26, 2023
Treatment with recombinant ADAMTS13, alleviates hypoxia/reoxygenation-induced pathologies in a mouse model of human sickle cell diseasePaolo Rossato, Helmut Glantschnig, Fabio Canneva, et al.
Haematologica|April 21, 2022
Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell diseasePaolo Rossato, Enrica Federti, Alessandro Matte, et al.
Expert Review of Clinical Pharmacology|February 10, 2015
Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodesPeter L Turecek, Brigitt Abbühl, Srilatha D Tangada, et al.
Thrombosis Research|March 4, 2021
Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19Peter L Turecek, Rachel C Peck, Savita Rangarajan, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 2, 2019
Evaluation of Factor VIII Polysialylation: Identification of a Longer-Acting Experimental Therapy in Mice and MonkeysHelmut Glantschnig, Alexander Bauer, Karima Benamara, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
British Journal of Haematology|May 19, 2004
Mutation of the surface-exposed amino acid Trp to Ala in the FVIII C2 domain results in defective secretion of the otherwise functional proteinSimone M Schatz, Klaus Zimmermann, Meinhard Hasslacher, et al.
Seminars in Thrombosis and Hemostasis|May 7, 2002
Recombinant von Willebrand factor-insight into structure and function through infusion studies in animals with severe von Willebrand diseaseHans Peter Schwarz, Uwe Schlokat, Artur Mitterer, et al.
Hamostaseologie|March 28, 2018
The role of ultralarge multimers in recombinant human von Willebrand factor - a review of physico-and biochemical studies and findings in in vivo models and in humans with von Willebrand diseasePeter L Turecek, Michael Spannagl, Thorsten Kragh, et al.
Journal of Thrombosis and Haemostasis : JTH|January 26, 2023
Treatment with recombinant ADAMTS13, alleviates hypoxia/reoxygenation-induced pathologies in a mouse model of human sickle cell diseasePaolo Rossato, Helmut Glantschnig, Fabio Canneva, et al.
Haematologica|April 21, 2022
Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell diseasePaolo Rossato, Enrica Federti, Alessandro Matte, et al.
Expert Review of Clinical Pharmacology|February 10, 2015
Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodesPeter L Turecek, Brigitt Abbühl, Srilatha D Tangada, et al.
Thrombosis Research|March 4, 2021
Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19Peter L Turecek, Rachel C Peck, Savita Rangarajan, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 2, 2019
Evaluation of Factor VIII Polysialylation: Identification of a Longer-Acting Experimental Therapy in Mice and MonkeysHelmut Glantschnig, Alexander Bauer, Karima Benamara, et al.
Pageof 2